Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,841 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 822 · Balance 37,297 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 2 · 2026-09-15 · Exercise / conversion · Acquired 1,019 · Balance 38,316 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 3 · 2026-09-15 · Exercise / conversion · Acquired 2,255 · Balance 40,571 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 4 · 2026-09-15 · Sale · Disposed 4,730 · Balance 35,841 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.52 · Expires 2029-11-20 | Direct | 6,574 |
Reported balance
After 2026-09-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-15 · Exercise / conversion · Disposed 822 · Balance 6,574 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2033-05-31 | Direct | 8,144 |
Reported balance
After 2026-09-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-15 · Exercise / conversion · Disposed 1,019 · Balance 8,144 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2034-06-14 | Direct | 18,032 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 2,255 · Balance 18,032 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
F2: The option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2020 Filed Aug 21, 2020 18:19 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 5,000 | $1.68 | $8,400.00 |
DisclosureSEC source: 0001567619-20-015854 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 21:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,076 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-015772 · doc1.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,667 Underlying: Common Stock · 5,076 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F3 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 21:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 5,076 | $1.68 | $8,527.68 |
DisclosureSEC source: 0001567619-20-015772 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 20:12 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,110 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-20-015690 · doc1.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,550 Underlying: Common Stock · 6,110 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F3 · derivative.exercise_date: The option vests monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 20:12 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 6,110 | $0.58 | $3,545.02 |
DisclosureSEC source: 0001567619-20-015690 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 67 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-014341 · doc1.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,419 Underlying: Common Stock · 67 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option vests monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,733 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001567619-20-014341 · doc1.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,010 Underlying: Common Stock · 2,733 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option vests monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 67 | $25.63 | $1,717.22 |
DisclosureSEC source: 0001567619-20-014341 · doc1.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,992 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $25.22 to $25.94, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 67 | $1.68 | $112.56 |
DisclosureSEC source: 0001567619-20-014341 · doc1.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,733 | $25.63 | $70,047.06 |
DisclosureSEC source: 0001567619-20-014341 · doc1.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,992 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $25.22 to $25.94, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 2,733 | $1.68 | $4,591.44 |
DisclosureSEC source: 0001567619-20-014341 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 22:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,110 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001567619-20-006468 · doc1.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,660 Underlying: Common Stock · 6,110 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares. F3 · derivative.exercise_date: The option vests monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 22:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 6,110 | $0.58 | $3,545.02 |
DisclosureSEC source: 0001567619-20-006468 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares. Read SEC document |
| February 27, 2020 Filed Mar 4, 2020 02:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $27.61 | $0.00 |
DisclosureSEC source: 0001567619-20-005553 · doc1.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-02-27 F4 · derivative.exercise_date: The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024. Read SEC document |
| February 27, 2020 Filed Mar 4, 2020 02:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-005553 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,882 F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024. Read SEC document |
| February 04, 2020 Filed Feb 4, 2020 23:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionSeries A Preferred Stock · Derivative | 24,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006603 · doc4.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 24,991 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 04, 2020 Filed Feb 4, 2020 23:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionCommon Stock | 24,991 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-006603 · doc4.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 24,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.